Literature DB >> 21447772

Erythromycin to promote bedside placement of a self-propelled nasojejunal feeding tube in non-critically ill patients having pancreatitis: a randomized, double-blind, placebo-controlled study.

Sven van den Bosch1, Ellen Witteman, YuHan Kho, Adriaan C I T L Tan.   

Abstract

BACKGROUND: Postpyloric enteral feeding often requires endoscopic or fluoroscopic placement of a feeding tube. Self-propelled feeding tubes are designed to facilitate spontaneous migration into the jejunum. This study aimed to assess the rate of success and time to migrate a self-propelled feeding tube to jejunal position using erythromycin, a prokinetic agent.
METHODS: Non-critically ill patients with pancreatitis who required jejunal enteral feeding were included. A self-propelled nasoenteric feeding tube was placed into the stomach using either placebo or erythromycin. At 24 and 48 hours after initial placement, an abdominal x-ray was taken to determine the position of the tube.
RESULTS: Forty subjects were included and randomized. After 48 hours, there was no difference in the rates of success between placebo 56% (9/16) and erythromycin 50% (10/20) (P = .71).
CONCLUSIONS: Self-propelled feeding tubes migrated into the jejunum in 53% of the subjects within 48 hours. However, this study failed to determine any benefit of erythromycin in terms of success or time to migrate to jejunal position using a self-propelled feeding tube. Selection of subjects without impaired motility and tachyphylaxis may have contributed to clinical failure of erythromycin as a prokinetic agent in this study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447772     DOI: 10.1177/0884533611399924

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  6 in total

Review 1.  Endoscopic- versus x-ray-guidance for placement of nasojejunal tubes in critically ill patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Guanzhen Lu; Qin Xiang; Sha Wang; Mingyue Pan; Xu Xiang; Yanling Yang; Xinyan Shi
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

2.  Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial.

Authors:  Bei Hu; Heng Ye; Cheng Sun; Yichen Zhang; Zhigang Lao; Fanghong Wu; Zhaohui Liu; Linxi Huang; Changchun Qu; Lewu Xian; Hao Wu; Yingjie Jiao; Junling Liu; Juyu Cai; Weiying Chen; Zhiqiang Nie; Zaiyi Liu; Chunbo Chen
Journal:  Crit Care       Date:  2015-02-13       Impact factor: 9.097

Review 3.  Erythromycin for Promoting the Postpyloric Placement of Feeding Tubes: A Systematic Review and Meta-Analysis.

Authors:  Qing-Jun Jiang; Cai-Feng Jiang; Qi-Tong Chen; Jian Shi; Bin Shi
Journal:  Gastroenterol Res Pract       Date:  2018-04-03       Impact factor: 2.260

4.  Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial.

Authors:  Bei Hu; Xin Ouyang; Liming Lei; Cheng Sun; Ruibin Chi; Jian Guo; Wenlong Guo; Yanlin Zhang; Yong Li; Daoyong Huang; Huafeng Sun; Zhiqiang Nie; Jieyang Yu; Yuan Zhou; Hao Wang; Jinhe Zhang; Chunbo Chen
Journal:  Intensive Care Med       Date:  2018-11-21       Impact factor: 17.440

5.  Intravenous Metoclopramide to Improve the Success Rate of Blind Bedside Post-pyloric Placement of Feeding Tube in Critically Ill Children: A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Sirima Ketsuwan; Pornthep Tanpowpong; Nichanan Ruangwattanapaisarn; Supatra Phaopant; Nattanicha Suppalarkbunlue; Chula Kooanantkul; Nattachai Anantasit; Jarin Vaewpanich
Journal:  Front Pediatr       Date:  2021-12-22       Impact factor: 3.418

6.  Experience in Bedside Placement, Clinical Validity, and Cost-Efficacy of a Self-Propelled Nasojejunal Feeding Tube.

Authors:  Carolina Puiggròs; Rosa Molinos; M Dolors Ortiz; Montserrat Ribas; Carlos Romero; Concepcion Vázquez; Hegoi Segurola; Rosa Burgos
Journal:  Nutr Clin Pract       Date:  2015-07-24       Impact factor: 3.080

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.